Skip to main content
Premium Trial:

Request an Annual Quote

Signal Genetics Q3 Revenues Move up 32 Percent

NEW YORK(GenomeWeb) – Signal Genetics said on Friday that its third quarter revenues increased 32 percent year over year. 

For the three months ended Sept. 30, the Carlsbad, Calif.-based cancer diagnostics firm said that revenues rose to $1.3 million from $983,589 in the year-ago quarter. 

"During the third quarter, we continued to execute on our business strategy by significantly growing our revenue, extending a key partnership and expanding our leadership team," Signal President and CEO Samuel Riccitelli said in a statement. 

During the quarter, the company hired Tamara Seymour as its CFO and Michael Cerio as senior vice president, commercial strategy and business development, and in September, it reached a deal to exclusively provide gene array clinical genetic testing services to the University of Arkansas for Medical Sciences. 

Signal's net loss for the third quarter rose to $1.6 million, or $.43 per share, from a net loss of $879,635, or $.35 per share, a year ago. The company went public in June and used about 3.8 million shares to calculate its loss on a per-share basis for the recently completed quarter, compared to 2.7 million shares in the year-ago period.

Its R&D spending was up to $76,214 from $46,604 year over year, while its SG&A spending more than doubled to $1.3 million from $535,444.

Signal finished the quarter with $6.4 million in cash and $50,236 in restricted cash, it said. 

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.